Semaglutide → Inappropriate schedule of product administration — Audit-grade candidate (scan)

← All findings ⬇ Download signed audit packet

Ledger entry · candidate

Semaglutide → Inappropriate schedule of product administration — Audit-grade candidate (scan)

Drug: semaglutide · AE: Inappropriate schedule of product administration

Discovered via single-drug scan of semaglutide. PRR = 3.34 (95% CI 3.11–3.59), n = 729 cases. Pre-reg locked at submission time.

Disproportionality

PRR: 3.343443922349501 (95% CI 3.11–3.59)
Yates χ²: 1199.9791881107706
Cases (case-drug + AE): n = 729
Verdict: PASSES_ALL_GATES — PRR=3.34 (95% CI 3.11–3.59), n=729 cases; flagged for clinical expert review, NOT for external escalation without manual verification

Top reactions in cohort

MedDRA PT	n
No reactions surfaced in cohort.

Source: openFDA FAERS, Caliper Engine v0. Pre-registration sha1 locked at submission time; ledger entry signed with platform Ed25519 key.

Independent Verification & Validation

Every finding includes an in-engine adversary review at no cost. For findings you plan to cite in a regulatory submission, scientific publication, or board-grade decision, we offer an additional layer of independent, audit-grade verification — reviewed by an externally-trained system that has never seen your data, your training corpus, or our hardware, and cryptographically signed.

Reference: a29de24c19020d4c8d5a6b30e8ab954770c5e6e3